Sucampo Releases Positive Phase III Data For Amitiza In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Sucampo's chronic idiopathic constipation treatment Amitiza (lubiprostone) may soon have a chance at a second life in a new market after the company announced positive results of a pivotal Phase III trial in Japanese patients